All In Biotech

Drug Trial Radar · NCT03390387

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

Last checked: Nov 19, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,000

Planned (sponsor's estimate)

Start

Nov 2015

Primary completion

Nov 2020

Study completion Nov 2025

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY 1. Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? 2. Will the new protocol is effective and feasible in patients older than 15 years, and especially in young adults? 3. Whether the intermittent dexamethasone administration in induction will result in a decrease in toxicity and mortality without loss of efficacy? 4. Whether the methylprednisolone administration as basic glucocorticoids during induction, consolidation and maintenance therapy will lead to decrease of severe infections and early mortality rate, improve survival and therapy compliance in adolescents and young adults with B-precursor ALL? 5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial WBC≥100,000/µl will improve treatment outcome? 6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and improve survival?

Conditions

  • Childhood Acute Lymphoblastic Leukemia

Interventions

  • Dexamethasone continuousDrug

    6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.

  • Dexamethasone intermittentDrug

    6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.

  • DexamethasoneDrug

    Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely. Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372). Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.

  • MethylprednisoloneDrug

    Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely. Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372). Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.

  • DaunorubicinDrug

    Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).

  • IdarubicinDrug

    Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).

  • BortezomibDrug

    1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).

  • Second phase of inductionDrug

    Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)

  • Standard induction therapyDrug

    Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)

  • Standard consolidation therapyDrug

    Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: 3 years, 5 years and 10 years after study start
  2. Overall survivalTime frame: 3 years, 5 years and 10 years after study start
  3. Cumulative incidence of relapseTime frame: 3 years, 5 years and 10 years after study start

Locations

58 sites in 5 countries. Site status is shown where the registry gives one.

  • prof. R.O.Eolyan Hematology Center

    Yerevan, Armenia · Completed

  • Republican Research and Practical Center of Radiation Medicine and Human Ecology

    Homyel, Belarus · Recruiting

  • Republic Research and Practical Center of Pediatric Oncology, Hematology and Immunology

    Minsk, Belarus · Recruiting

  • Mogilev Regional Children's Hospital

    Mogilev, Belarus · Recruiting

  • National Oncology and Hematology Center, Ministry of Health of the Kyrgyz Republic

    Bishkek, Kyrgyzstan · Completed

  • Arkhangelsk Regional Clinical Children's Hospital

    Arkhangelsk, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Astrakhan, Russia · Recruiting

  • Altay Regional Clinical Children's Hospital

    Barnaul, Russia · Recruiting

  • Amur Regional Clinical Children's Hospital

    Blagoveshchensk, Russia · Recruiting

  • Bryansk Regional Children's Hospital

    Bryansk, Russia · Recruiting

  • Chelyabinsk Regional Clinical Children's Hospital

    Chelyabinsk, Russia · Recruiting

  • Transbaikal Regional Oncology Dispensary

    Chita, Russia · Recruiting

  • Irkutsk Regional Children Clinical Hospital

    Irkutsk, Russia · Recruiting

  • Ivanovo Regional Clinical Hospital

    Ivanovo, Russia · Recruiting

  • Republic Clinical Children's Hospital

    Izhevsk, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Khabarovsk, Russia · Recruiting

  • Kirov Research Institute of Hematology and Blood Transfusion

    Kirov, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Krasnodar, Russia · Recruiting

  • Krasnoyarsk Territorial Clinical Children's Hospital

    Krasnoyarsk, Russia · Recruiting

  • Kurgan Regional Clinical Children's Hospital

    Kurgan, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Kursk, Russia · Recruiting

  • Regional Children's Hospital

    Lipetsk, Russia · Recruiting

  • Republic Children's Clinical Hospital

    Makhachkala, Russia · Recruiting

  • Morozov Children's Municipal Clinical Hospital

    Moscow, Russia · Recruiting

  • Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev

    Moscow, Russia · Recruiting

  • Russian Children's Clinical Hospital

    Moscow, Russia · Recruiting

  • Murmansk Clinical Children's Hospital

    Murmansk, Russia · Recruiting

  • Republic Clinical Children's Hospital

    Nal'chik, Russia · Recruiting

  • Nizhnevartovsk Regional Clinical Children's Hospital

    Nizhnevartovsk, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Nizhny Novgorod, Russia · Recruiting

  • Novokuznetsk Municipal Clinical Children's Hospital N4

    Novokuznetsk, Russia · Recruiting

  • Novosibirsk Central District Clinical Hospital

    Novosibirsk, Russia · Recruiting

  • Orenburg Regional Clinical Oncology Dispensary

    Orenburg, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Oryol, Russia · Recruiting

  • Perm Territorial Clinical Children's Hospital

    Perm, Russia · Recruiting

  • Regional Clinical Children's Hospital

    Rostov-on-Don, Russia · Recruiting

  • Rostov Research Institute of Oncology

    Rostov-on-Don, Russia · Recruiting

  • N. Dmitrieva Ryazan Regional Clinical Children's Hospital

    Ryazan, Russia · Recruiting

  • Almazov National Medical Research Center

    Saint Petersburg, Russia · Recruiting

  • Children's Municipal Hospital N1

    Saint Petersburg, Russia · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.